{
  "docId": "019de071-f579-76ad-bea5-b34da2c83a75",
  "docSlug": "563487226462eb4ab63630eb9b74a5cf",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 42,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 42,
  "notes": "Includes scatter plot (A) and box plot (B) for T-cell proliferation data, plus summary statistics for biliary tract cancer trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f579-76ad-bea5-b34da2c83a75/8",
  "deckHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75",
  "deckJsonHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75.json",
  "deckAnchorHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.42,
        "w": 0.22,
        "x": 0.26,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Study 22 HCC T-cell proliferation data (B)",
      "attrs": null,
      "subkind": "box",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9df6e33-e6fd-47d5-a0bc-59beae5baa83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.42,
        "w": 0.22,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Study 22 HCC T-cell proliferation data (A)",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96e12c92-a125-43e5-9c66-277503e2312a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.52,
        "y": 0.38
      },
      "kind": "list",
      "text": "121 patients enrolled with 1st-line biliary tract cancer; Imfinzi (+/- tremelimumab) in combination with gemcitabine and cisplatin; Combination was well tolerated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7402189d-180d-4609-8851-445d430dd880",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.44,
        "x": 0.04,
        "y": 0.68
      },
      "kind": "list",
      "text": "322 patients with advanced hepatocellular carcinoma randomised between arms",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f56c8055-67fd-45dd-97c9-21899a79832e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.46,
        "x": 0.51,
        "y": 0.81
      },
      "kind": "metric",
      "text": "Median OS: 18.1-mo for Imfinzi + gem/cis",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "409426ec-0b1b-4b5a-bc22-cb913b4d2c51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.46,
        "x": 0.03,
        "y": 0.81
      },
      "kind": "metric",
      "text": "Median OS: T300+D - 18.7-mo; Imfinzi - 13.6-mo",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c04ba1fc-82e7-42bc-b655-9dbbeeff6678",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.77,
        "x": 0.03,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "1. Kelley et al J Clin Oncol 39, 27: 2021 2991-3001 2. D-Y Oh et al ASCO 2020 J Clin Oncol 38, 15 suppl: 2020 4520. OS = overall survival; T300 = tremelimumab 300mg; mo = months; gem - = gemcitabine; cis = cisplatin",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86da9a6c-3727-4684-8539-2758f0f21e45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Imfinzi and tremelimumab",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d5f09e0-3c7d-4457-bbdd-cc65021b2589",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Phase II data in gastrointestinal cancers informed TOPAZ-1 and HIMALAYA designs",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1f5772a-6772-4892-89e4-678e75907f65",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "8378906b-bd6e-4d7d-b194-bf3958a22d78",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The deck highlights the comprehensive portfolio to combat cancer and the opportunity in GI tumours",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}